Crossmark

Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study

Crossref DOI link: https://doi.org/10.1038/s41409-026-02929-7

Published Online: 2026-06-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Chenxue https://orcid.org/0009-0008-3767-0071
Xue, Lei https://orcid.org/0000-0002-2821-9376
Wu, Miaomiao https://orcid.org/0009-0003-0307-6203
Li, Sujun https://orcid.org/0009-0000-4741-257X
Xu, Qianwen https://orcid.org/0000-0002-6198-0829
Liu, Kaichun

Li, Hui https://orcid.org/0009-0008-5594-0303
Xu, Hui

Yang, Liyun

Wang, Tao

Jin, Rong

Wang, Xingbing https://orcid.org/0000-0002-5591-2168
License Information

Text and Data Mining valid from 2026-06-04

Version of Record valid from 2026-06-04
More Information

Article History

Received: 17 June 2025

Revised: 26 April 2026

Accepted: 27 May 2026

First Online: 4 June 2026

Competing interests

: KL, LY, TW, and RJ are employees of Fundamenta Therapeutics, Ltd. Fundamenta Therapeutics, Ltd. provided ThisCAR-T cell products and support for cell manufacturing and quality control. These authors declare no other competing interests. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below